5,480 reports of this reaction
1.9% of all ADALIMUMAB FKJP reports
#3 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #3 most commonly reported adverse reaction for ADALIMUMAB FKJP, manufactured by Biocon Biologics Inc. There are 5,480 FDA adverse event reports linking ADALIMUMAB FKJP to RHEUMATOID ARTHRITIS. This represents approximately 1.9% of all 281,217 adverse event reports for this drug.
Patients taking ADALIMUMAB FKJP who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is a less commonly reported adverse event for ADALIMUMAB FKJP, but still significant enough to appear in the safety profile.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for ADALIMUMAB FKJP:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 5,480 FDA reports for ADALIMUMAB FKJP. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 1.9% of all adverse event reports for ADALIMUMAB FKJP, making it one of the most commonly reported side effect.
If you experience rheumatoid arthritis while taking ADALIMUMAB FKJP, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.